Quality of Life of Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) and Stevens-Johnson Syndrome (SJS) and/or Toxic Epidermal Necrolysis (TEN) Patients

References

• Indonesia Ministry of Health. Keputusan Menteri Kesehatan RI No. 676/Menkes/SK/V/2005 Tentang Pedoman Umum Pengadaan Obat Program Kesehatan Tahun 2005 (Guideline of Procurement of Health Program Drugs). Jakarta: Kementrian Kesehatan Republik Indonesia; 2005.
   Google Scholar
• Badan POM RI. Drug Safety for Patient Safety. Badan POM RI Bulletin Berita MESO. 2016;34(1):1–7.
   Google Scholar
• Vanini A, Hutomo M. Manifestasi klinis sindroma DRESS (Drug Reaction with Eosinophilia and Systemic Symptom) (clinical manifestation of DRESS (Drug Reaction with Eosinophilia and Systemic Symptom) syndrome. Berkala Ilmu Kesehatan Kulit Dan Kelamin. 2010;22(1):40–44.
   Google Scholar
• Borges SM, Caballero-Fonseca F, Capriles-Hulett A, Aveledo GL. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs an update. Pharmaceuticals. 2010;3(1):10–18. doi:10.3390/ph3010010
   Google Scholar
• Mehrholz D, Emilia A, Hers M. A retrospective study of DRESS – drug reaction with eosinophilia and systemic symptoms. Psychiatr Pol. 2017;51(6):1079–1093. doi:10.12740/PP/74358
   Web of Science ®Google Scholar
• Lin YF, Yang CH, Sindy H, et al. Severe cutaneous adverse reactions related to systemic antibiotics. Clin Infect Dis. 2014;58(10):1377–1385. doi:10.1093/cid/ciu126
   PubMed Web of Science ®Google Scholar
• De A, Rajagopalan M, Sarda A, Das S, Biswas P. Drug reaction with eosinophilia and systemic symptoms: an update and review of recent literature. Indian J Dermatol. 2018;63(1):30–40. doi:10.4103/ijd.IJD_582_17
   PubMed Web of Science ®Google Scholar
• Musette P, Janela B. New insights into drug reaction with eosinophilia and systemic symptoms pathophysiology. Front Med. 2017;4:179. doi:10.3389/fmed.2017.00179
   Web of Science ®Google Scholar
• Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387–1397. doi:10.1016/j.jid.2016.03.023
   PubMed Web of Science ®Google Scholar
• Putri ND, Mutiara H, Hasudungan H, Siberio HT, Sukohar A. Steven Johnson syndrome et causa paracetamol. J Medula UNILA. 2016;6(1):101–107.
   Google Scholar
• Abdulah R, Suwandiman TF, Handayani N, Destiani DP, Suwantika AA. Incidence, causative drugs, and economic consequences of drug-induced SJS, TEN, and SJS–TEN overlap and potential drug drug interactions during treatment: a retrospective analysis at an Indonesian referral hospital. Ther Clin Risk Manag. 2017;13:919–925. doi:10.2147/TCRM.S142226
   PubMed Web of Science ®Google Scholar
• Thong BYH. Stevens-Johnson syndrome/toxic epidermal necrolysis: an Asia-Pacific perspective. Asia Pac Allergy. 2013;3(4):215. doi:10.5415/apallergy.2013.3.4.215
   PubMedGoogle Scholar
• Yang MS, Kim JY, Kang MG, et al. Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea. Korean J Intern Med. 2017;34(1):195–201. doi:10.3904/kjim.2015.365
   Web of Science ®Google Scholar
• James J, Sammour YM, Virata AR, Nordin TA, Dumic I. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome secondary to furosemide: case report and review of literature. Am J Case Rep. 2018;19:163–170. doi:10.12659/AJCR.907464
   PubMed Web of Science ®Google Scholar
• Nogueira R, Franca M, Lobato MG, Belfort R, Souza CB, Gomes JÁP. Qualidade de vida dos pacientes portadores de síndrome de Stevens-Johnson. Arq Bras Oftalmol. 2003;66(1):67–70. doi:10.1590/S0004-27492003000100013
   Google Scholar
• Purba FD, Hunfeld JAM, Iskandarsyah A, et al. The Indonesian EQ-5D-5L Value Set. Pharmaco Economics. 2017;35(11):1153–1165. doi:10.1007/s40273-017-0538-9
   PubMed Web of Science ®Google Scholar
• Velasco-Tirado V, Alonso-Sardon M, Cosano-quero A, et al. Life threatening dermatoses: Stevens Johnson syndrome and toxic epidermal necrolysis, impact on the Spanish public health system (2010–2015). PLoS One. 2018;13(6):1–12. doi:10.1371/journal.pone.0198582
   Web of Science ®Google Scholar
• Rahmawati YW, Indramaya DM. Studi retrospektif: sindrom Stevens Johnson dan epidermal toksik (retrospective study: Stevens Johnson syndrome and toxic epidermal). Berkala Ilmu Kesehatan Kulit Dan Kelamin. 2018;28(2):68–76.
   Google Scholar
• Stella M, Clemente A, Bollero D, Risso D, Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens–Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. Burns. 2007;33(4):452–459. doi:10.1016/j.burns.2006.08.014
   Web of Science ®Google Scholar
• Wang L, Mei XL. Drug reaction with eosinophilia and systemic symptoms: retrospective analysis of 104 cases over one decade. Chin Med J. 2017;130(8):943–949. doi:10.4103/0366-6999.204104
   PubMed Web of Science ®Google Scholar
• Anna RW, Zhou L, Li Y, Phadke NA, Chow A, Kimberly GB. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome identified in the electronic health record allergy module. J Allergy Clin Immunol. 2019;7(2):633–640. doi:10.1016/j.jaip.2018.08.013
   Web of Science ®Google Scholar
• Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Act Derm Venereol. 2007;87(2):144–148. doi:10.2340/00015555-0214
   PubMed Web of Science ®Google Scholar
• Roongpisuthipong W, Sirikarn P, Theerawut K. Retrospective analysis of corticosteroid treatment in Stevens Johnson syndrome and/or toxic epidermal necrolysis over a period of 10 Years in Vajira Hospital, Navamindradhiraj University, Bangkok. Dermatol Res Pract. 2014;2014:1–5. doi:10.1155/2014/237821
   Google Scholar
• Lihite RJ, Mangala L, Ajoy B, Debeeka H, Sukhjinder S. A study on drug induced Stevens Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) and SJS-TEN overlap in a tertiary care hospital of Northeast India. J Young Pharm. 2016;8(2):149–153. doi:10.5530/jyp.2016.2.18
   Google Scholar
• Saka B, Akakpo AS, Teclessou JN, et al. Ocular and mucocutaneous sequelae among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in togo. Dermatol Res Pract. 2019;2019:30. doi:10.1155/2019/4917024
   Web of Science ®Google Scholar
• Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. J Plast Reconstr Aesthet Surg. 2016;69(6):736–741. doi:10.1016/j.bjps.2016.04.018
   Web of Science ®Google Scholar
• Chantaphakul H, Sanon T, Klaewsongkram J. Clinical characteristics and treatment outcome of Stevens Johnson syndrome and toxic epidermal necrolysis. Exp Ther Med. 2015;10:519–524. doi:10.3892/etm.2015.2549
   Web of Science ®Google Scholar
• Zavala S, O’Mahony M, Joyce C, Baldea AJ. How Does SCORTEN Score. J Burn Care Res. 2018;39(4):555–561. doi:10.1093/jbcr/irx016
   Web of Science ®Google Scholar
• Nishikaku AS, Gompertz OF, Disciplina DDI. Major emotional and physical complications among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2016;74(5):AB61.
   Web of Science ®Google Scholar
• Olteanu C, Shear NH, Chew HF, et al. Severe physical complications among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Drug Saf. 2018;41(3):277–284. doi:10.1007/s40264-017-0608-0
   Web of Science ®Google Scholar
• Dodiuk-Gad RP, Olteanu C, Feinstein A, et al. Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2016;175(2):422–424. doi:10.1111/bjd.14799
   PubMed Web of Science ®Google Scholar